Novel immunotherapy leads to complete regression of chemotherapy-resistant liver cancer in 3-year-old

A new report in the New England Journal of Medicine by researchers at Baylor College of Medicine, Texas Children's Hospital and Seattle Children's describes a complete regression of hepatoblastoma, the most common pediatric liver cancer, in a 3-year-old treated with a novel immunotherapy.

Read it at Medical Xpress ↗

← Front page